|Articles|July 20, 2016

Mitsubishi Tanabe Joins Certara’s Simcyp Consortium

Certara announces the addition of Mitsubishi Tanabe to its Simcyp Consortium as the group’s 34th biopharmaceutical company.

Certara announces the addition of Mitsubishi Tanabe to its Simcyp Consortium as the group’s 34th biopharmaceutical company. Mitsubishi Tanabe has also licensed its proprietary Simcyp Population-based Simulator, which enables companies to study drug activity in virtual patients.

Read the full release here

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Mitsubishi Tanabe Joins Certara’s Simcyp Consortium

Related Content

Protocol Design Doesn't Fail in the Protocol, It Fails in Transition to Trial

The Data Behind Reducing Trial Burden Without Sacrificing Quality

ACT Brief: Tavneos Trial Integrity Issues, Selective Safety Data Regulatory Pathways, and FDA PreCheck Program Launch

Why Four Regulatory Scenarios Could De-Risk Selective Safety Data Collection

NEJM Retracts Tavneos Trial Paper as FDA, EMA Both Move to Pull Amgen Drug From Market

Trending on Applied Clinical Trials Online

NEJM Retracts Tavneos Trial Paper as FDA, EMA Both Move to Pull Amgen Drug From Market

ACT Brief: Tavneos Trial Integrity Issues, Selective Safety Data Regulatory Pathways, and FDA PreCheck Program Launch

ACT Brief: Real-Time Trial Infrastructure Gaps, Built-In Data Security, and AI-Enabled CDMO Value

Real-Time Clinical Trials: What the FDA's Push Toward Continuous Oversight Means for Sponsors

ACT Brief: DIA Leadership and Infrastructure Priorities, Real-Time Data Review Readiness, and CLL Treatment Expansion